Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Non-Current Debt: 2012-2025

Historic Non-Current Debt for Altimmune (ALT) over the last 9 years, with Sep 2025 value amounting to $14.4 million.

  • Altimmune's Non-Current Debt was N/A to $14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year change of. This contributed to the annual value of $4.6 million for FY2022, which is 215.06% up from last year.
  • Latest data reveals that Altimmune reported Non-Current Debt of $14.4 million as of Q3 2025, which was up 0.79% from $14.3 million recorded in Q2 2025.
  • Altimmune's 5-year Non-Current Debt high stood at $14.4 million for Q3 2025, and its period low was $1.5 million during Q4 2021.
  • Its 2-year average for Non-Current Debt is $8.3 million, with a median of $4.4 million in 2023.
  • In the last 5 years, Altimmune's Non-Current Debt declined by 20.48% in 2021 and then surged by 215.06% in 2022.
  • Over the past 4 years, Altimmune's Non-Current Debt (Quarterly) stood at $1.5 million in 2021, then surged by 215.06% to $4.6 million in 2022, then fell by 4.46% to $4.3 million in 2023, then reached $14.4 million in 2025.
  • Its Non-Current Debt was $14.4 million in Q3 2025, compared to $14.3 million in Q2 2025 and $4.3 million in Q3 2023.